/Companies

Rakuten Med

San Diego, US · Founded 2010 · 1 known investors

Find your way into Rakuten Med

Sign up to see every warm intro you have to Rakuten Med

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Rakuten Med team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Rakuten Medical is a global biotechnology company that develops and commercializes precision cell-targeting photoimmunotherapy treatments for cancer using its proprietary Alluminox platform. The company focuses on creating innovative cancer treatment options and bringing them to patients worldwide.

Founders & leadership

ABAbhijit Bhatia
Abhijit BhatiaChief Operating Officer (COO)Abhijit Bhatia is an executive officer at Rakuten Medical, a biotechnology company developing precision cell-targeting photoimmunotherapy cancer treatments using its Alluminox platform. He brings expertise in business strategy, corporate partnerships, deal negotiation, and commercialization within the life sciences sector.
TP
Tiffany PiecewiczGeneral CounselTiffany Piecewicz is an attorney with 15+ years of experience in corporate governance, intellectual property litigation, employment law, and contract disputes across multinational organizations. She has managed strategic matters for cases valued up to $14B and has worked on international corporate compliance projects in Europe.
SS
Suzane SanChief People OfficerSuzane San is an Executive Officer at Rakuten Medical with over 15 years of experience in people operations and organizational development within the biotechnology sector. Her background includes designing and implementing HR programs, advising on personnel matters, and supporting organizational growth across biotech companies.
MGMiguel Garcia-Guzman
Miguel Garcia-GuzmanBoard Member
MM
Minami MaedaExecutive
TSToshiaki Suzuki
Toshiaki SuzukiSenior Director
SSScott Salka
Scott SalkaChief Executive Officer2010–2015
HKHiroyuki Kodama
Hiroyuki KodamaChief Product Officer
LCLouise Chang
Louise ChangChief Strategy OfficerLouise Chang is Chief Strategy Officer at Rakuten Medical, where she oversees corporate strategy, investor relations, and clinical program governance. She has over a decade of healthcare industry experience, including prior roles at Johnson & Johnson China and E-SUN Commercial Bank.
AT
Amy ThorneExecutive
AMAnthony Manibusan
Anthony ManibusanVice President, Head of CMC
HD
Hassan DanesiExecutive

Investors · 1

Reported raises · per SEC filings

Form D private placements

$908.3M disclosed across 17 rounds · 2014–2026

▶$9MraisedOct 2026 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Maeda MinamiExecutive Officer
  • David ChaoDirector
  • Miguel Garcia-GuzmanDirector
  • Hiroshi MikitaniDirector
  • Hiroshi MoriDirector
  • Ken TakeshitaDirector
  • Christophe WeberDirector
  • Nitin NohriaDirector
  • Eiichi KagaDirector
  • Mazen DarwazehDirector
  • Tiffany PiecewiczExecutive Officer
  • Abhijit BhatiaExecutive Officer
  • Toshiaki SuzukiExecutive Officer
  • Suzane SanExecutive Officer
  • Hiroyuki KodamaExecutive Officer
  • Louise ChangExecutive Officer
  • Amy ThorneExecutive Officer
  • Anthony ManibusanExecutive Officer
  • Hassan DanesiExecutive Officer
Offering amount
$9M
Amount sold
$9M
First sale
Aug 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$111.5MraisedApr 2026 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Hiroshi MoriDirector
  • Hiroyuki KodamaExecutive Officer
  • Hiroshi MikitaniExecutive Officer, Director
  • Suzane SanExecutive Officer
  • David ChaoDirector
  • Toshiaki SuzukiExecutive Officer
  • Carlos GarciaExecutive Officer
  • Maeda MinamiExecutive Officer
  • Abhijit BhatiaExecutive Officer
  • Kentaro HyakunoDirector
  • Nitin NohriaDirector
  • Mazen DarwazahDirector
  • Eiichi KagaDirector
  • Miguel Garcia-GuzmanDirector
  • Tiffany PiecewiczExecutive Officer
Offering amount
$116.7M
Amount sold
$111.5M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.9MraisedMay 2025 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Abhijit BhatiaExecutive Officer
  • Nitin NohriaDirector
  • David ChaoDirector
  • Tiffany PiecewiczExecutive Officer
  • Mazen DarwazahDirector
  • Suzane SanExecutive Officer
  • Hiroshi MikitaniExecutive Officer, Director
  • Hiroshi MoriDirector
  • Miguel Garcia-GuzmanDirector
  • Eiichi KagaDirector
  • Minami MaedaExecutive Officer
  • Toshiaki SuzukiExecutive Officer
  • Carlos GarciaExecutive Officer
  • Kentaro HyakunoDirector
Offering amount
$1.9M
Amount sold
$1.9M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.2MraisedMar 2024 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David ChaoDirector
  • Carlos GarciaExecutive Officer
  • Mazen DarwazahDirector
  • Suzane SanExecutive Officer
  • Hiroshi MoriDirector
  • Hiroshi MikitaniExecutive Officer, Director
  • Kentaro HyakunoDirector
  • Hiroshi TakasawaDirector
  • Nitin NohriaDirector
  • Miguel Garcia-GuzmanDirector
  • Takashi ToraishiExecutive Officer, Director
  • Abhijit BhatiaExecutive Officer
  • Agatha MartindaleExecutive Officer
  • Minami MaedaExecutive Officer
  • Tiffany PiecewiczExecutive Officer
  • Toshiaki SuzukiExecutive Officer
Offering amount
$4.2M
Amount sold
$4.2M
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedOct 2023 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kentaro HyakunoDirector
  • Mazen DarwazehDirector
  • Hiroshi MoriDirector
  • Nitin NohriaDirector
  • David ChaoDirector
  • Toshiaki SuzukiExecutive Officer
  • Takashi ToraishiExecutive Officer, Director
  • Abhijit BhatiaExecutive Officer
  • Tiffany PiecewiczExecutive Officer
  • Hiroshi TakasawaDirector
  • Hiroshi MikitaniExecutive Officer, Director
  • Miguel Garcia-GuzmanDirector
  • Carlos GarciaExecutive Officer
Offering amount
$2.2M
Amount sold
$2.2M
First sale
Jun 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$104.8MraisedSep 2023 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tiffany PiecewiczExecutive Officer
  • Miguel Garcia-GuzmanDirector
  • Nitin NohriaDirector
  • David ChaoDirector
  • Carlos GarciaExecutive Officer
  • Mazen DarwazehDirector
  • Takashi ToraishiExecutive Officer, Director
  • Kentaro HyakunoDirector
  • Hiroshi MikitaniExecutive Officer, Director
  • Abhijit BhatiaExecutive Officer
  • Hiroshi MoriDirector
  • Hiroshi TakasawaDirector
Offering amount
$123.7M
Amount sold
$104.8M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$70MraisedDec 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Miguel Garcia-GuzmanDirector
  • Carlos GarciaExecutive Officer
  • Tiffany PiecewiczExecutive Officer
  • Hiroshi MoriDirector
  • David ChaoDirector
  • Kentaro HyakunoDirector
  • Abhijit BhatiaExecutive Officer
  • Takashi ToraishiExecutive Officer, Director
  • Nitin NohriaDirector
  • Hiroshi MikitaniExecutive Officer, Director
  • Hiroshi TakasawaDirector
Offering amount
$90M
Amount sold
$70M
First sale
Dec 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$166MraisedJul 2021 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Miguel Garcia-GuzmanExecutive Officer, Director
  • David ChaoDirector
  • Takashi ToraishiExecutive Officer, Director
  • Kentaro HyakunoDirector
  • Ann McGuireExecutive Officer
  • Hiroshi MoriDirector
  • Carlos GarciaExecutive Officer
  • Hiroshi TakasawaDirector
  • Nitin NohriaDirector
  • Hiroshi MikitaniExecutive Officer, Director
Offering amount
$291M
Amount sold
$166M
Sales commissions
$3M
Placement agents
TAP Securities LLC, Momentum Capital Markets, LLC
First sale
Jul 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Companies working in the same space as Rakuten Med.

Frequently asked questions

What does Rakuten Med do?
Rakuten Medical is a global biotechnology company that develops and commercializes precision cell-targeting photoimmunotherapy treatments for cancer using its proprietary Alluminox platform. The company focuses on creating innovative cancer treatment options and bringing them to patients worldwide.
Who are Rakuten Med's investors?
Rakuten Med's investors include Taiwania Capital.
How much funding has Rakuten Med raised?
Rakuten Med has disclosed $908.3M raised across 17 rounds.
Where is Rakuten Med headquartered?
Rakuten Med is headquartered in San Diego, US.